Amgen, Simcere partner for biosimilars in China

Amgen Inc. (NASDAQ:AMGN) and Simcere Pharmaceutical Group (Nanjing, China) partnered to exclusively co-develop and commercialize biosimilars in China. The agreement includes four biosimilars from Amgen in inflammation and oncology, including ABP 501 and Mvasi bevacizumab-awwb

Read the full 357 word article

How to gain access

Continue reading with a
two-week free trial.